U.S. Markets closed

PDL BioPharma, Inc. (PDLI)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.37-0.02 (-0.84%)
At close: 4:00PM EDT
People also watch
MYGNINCYVRTXENZNALKS

PDL BioPharma, Inc.

932 Southwood Boulevard
Incline Village, NV 89451
United States
775-832-8500
http://www.pdl.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedAge
Mr. John Peter McLaughlin J.D.CEO, Pres & DirectorN/AN/A65
Mr. Peter S. GarciaChief Financial Officer and VPN/AN/A55
Mr. Steffen Pietzke CPAChief Accounting Officer and VP of Fin.N/AN/A45
Mr. Christopher L. Stone J.D.VP, Gen. Counsel and Sec.N/AN/A53
Mr. Danny J. Hart Jr., J.D.VP of Bus. Devel.N/AN/A41
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Corporate Governance

PDL BioPharma, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.